BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 17804841)

  • 1. Efficacy and safety of epoetin alfa in critically ill patients.
    Corwin HL; Gettinger A; Fabian TC; May A; Pearl RG; Heard S; An R; Bowers PJ; Burton P; Klausner MA; Corwin MJ;
    N Engl J Med; 2007 Sep; 357(10):965-76. PubMed ID: 17804841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.
    Corwin HL; Gettinger A; Pearl RG; Fink MP; Levy MM; Shapiro MJ; Corwin MJ; Colton T;
    JAMA; 2002 Dec; 288(22):2827-35. PubMed ID: 12472324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin alfa protocol and multidisciplinary blood-conservation program for critically ill patients.
    Pell LJ; Martin BS; Shirk MB
    Am J Health Syst Pharm; 2005 Feb; 62(4):400-5. PubMed ID: 15745893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood conservation in the critically ill.
    Thomas J; Martinez A
    Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S11-8. PubMed ID: 17687066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin.
    Napolitano LM; Fabian TC; Kelly KM; Bailey JA; Block EF; Langholff W; Enny C; Corwin HL
    J Trauma; 2008 Aug; 65(2):285-97; discussion 297-9. PubMed ID: 18695463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
    Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
    Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting anemia with erythropoietin during critical illness.
    Cook D; Crowther M
    N Engl J Med; 2007 Sep; 357(10):1037-9. PubMed ID: 17804850
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythropoietic agents for anemia of critical illness.
    Shermock KM; Horn E; Rice TL
    Am J Health Syst Pharm; 2008 Mar; 65(6):540-6. PubMed ID: 18319499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a place for epoetin alfa in managing anemia during critical illness?
    Givens M; Lapointe M
    Clin Ther; 2004 Jun; 26(6):819-29. PubMed ID: 15262453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
    Moebus V; Jackisch C; Schneeweiss A; Huober J; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Runnebaum IB; Hinke A; Kreienberg R; Untch M;
    J Natl Cancer Inst; 2013 Jul; 105(14):1018-26. PubMed ID: 23860204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.
    Najjar SS; Rao SV; Melloni C; Raman SV; Povsic TJ; Melton L; Barsness GW; Prather K; Heitner JF; Kilaru R; Gruberg L; Hasselblad V; Greenbaum AB; Patel M; Kim RJ; Talan M; Ferrucci L; Longo DL; Lakatta EG; Harrington RA;
    JAMA; 2011 May; 305(18):1863-72. PubMed ID: 21558517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the Long Term Trauma Outcomes Study.
    Luchette FA; Pasquale MD; Fabian TC; Langholff WK; Wolfson M
    Am J Surg; 2012 Apr; 203(4):508-16. PubMed ID: 22177550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
    Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
    Afdhal NH; Dieterich DT; Pockros PJ; Schiff ER; Shiffman ML; Sulkowski MS; Wright T; Younossi Z; Goon BL; Tang KL; Bowers PJ;
    Gastroenterology; 2004 May; 126(5):1302-11. PubMed ID: 15131791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
    McCullough PA; Barnhart HX; Inrig JK; Reddan D; Sapp S; Patel UD; Singh AK; Szczech LA; Califf RM
    Am J Nephrol; 2013; 37(6):549-58. PubMed ID: 23735819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.